VALACYCLOVIR HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
When do Valacyclovir Hydrochloride patents expire, and when can generic versions of Valacyclovir Hydrochloride launch?
Valacyclovir Hydrochloride is a drug marketed by Adaptis, Apotex, Aurobindo Pharma, Chartwell Rx, Cipla, Hetero Labs Ltd V, Hikma, Jubilant Generics, Mylan, Mylan Pharms Inc, Sandoz, Sun Pharm Inds Ltd, Teva Pharms, Watson Labs Inc, Yiling, and Zydus Lifesciences. and is included in sixteen NDAs.
The generic ingredient in VALACYCLOVIR HYDROCHLORIDE is valacyclovir hydrochloride. There are twenty-three drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the valacyclovir hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Valacyclovir Hydrochloride
A generic version of VALACYCLOVIR HYDROCHLORIDE was approved as valacyclovir hydrochloride by SUN PHARM INDS LTD on January 31st, 2007.
Summary for VALACYCLOVIR HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 16 |
NDAs: | 16 |
Finished Product Suppliers / Packagers: | 41 |
Raw Ingredient (Bulk) Api Vendors: | 90 |
Clinical Trials: | 120 |
Patent Applications: | 1,375 |
Formulation / Manufacturing: | see details |
DailyMed Link: | VALACYCLOVIR HYDROCHLORIDE at DailyMed |